These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16082989)

  • 1. Appropriate and timely empirical antimicrobial treatment of icu infections--a role for carbapenems.
    Colardyn F
    Acta Clin Belg; 2005; 60(2):51-62. PubMed ID: 16082989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems.
    Tellado JM; Wilson SE
    Surg Infect (Larchmt); 2005; 6(3):329-43. PubMed ID: 16201943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current guidelines for the treatment of severe pneumonia and sepsis.
    Bodmann KF
    Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiological surveillance and antimicrobial stewardship minimise the need for ultrabroad-spectrum combination therapy for treatment of nosocomial infections in a trauma intensive care unit: an audit of an evidence-based empiric antimicrobial policy.
    Ramsamy Y; Muckart DJ; Han KS
    S Afr Med J; 2013 Mar; 103(6):371-6. PubMed ID: 23725954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems.
    Kollef MH
    Respir Care; 2004 Dec; 49(12):1530-41. PubMed ID: 15571647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality.
    Zahar JR; Timsit JF; Garrouste-Orgeas M; Français A; Vesin A; Descorps-Declere A; Dubois Y; Souweine B; Haouache H; Goldgran-Toledano D; Allaouchiche B; Azoulay E; Adrie C
    Crit Care Med; 2011 Aug; 39(8):1886-95. PubMed ID: 21516036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antimicrobial therapy in severe infections with multidrug-resistant Gram-negative bacterias].
    Duszyńska W
    Anestezjol Intens Ter; 2010; 42(3):160-6. PubMed ID: 21413423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients.
    Warren DK; Hill HA; Merz LR; Kollef MH; Hayden MK; Fraser VJ; Fridkin SK
    Crit Care Med; 2004 Dec; 32(12):2450-6. PubMed ID: 15599150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doripenem.
    Anderson DL
    Drugs Today (Barc); 2006 Jun; 42(6):399-404. PubMed ID: 16845443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gram-negative bacterial resistance: evolving patterns and treatment paradigms.
    Kollef MH
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S85-8. PubMed ID: 15712101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of an antibiotic cycling program on empirical therapy for gram-negative infections.
    Merz LR; Warren DK; Kollef MH; Fridkin SK; Fraser VJ
    Chest; 2006 Dec; 130(6):1672-8. PubMed ID: 17166981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The drug resistance of pathogenic bacteria of nosocomial infections in surgical intensive care unit].
    Chen J; Li LF; Guan XD; Chen DM; Chen MY; Ouyang B; Huang SW; Wu JF
    Zhonghua Wai Ke Za Zhi; 2006 Sep; 44(17):1189-92. PubMed ID: 17147864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The vicissitude of pathogenic bacteria isolated from critically ill patients in an intensive care unit during a period of using antibiotics].
    Wei HJ; Liu LL; Xiaoli LY; Wang YP; Huang D; Pian HY; Zhu YC
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Jan; 21(1):36-9. PubMed ID: 19141190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward.
    Hughes MG; Evans HL; Chong TW; Smith RL; Raymond DP; Pelletier SJ; Pruett TL; Sawyer RG
    Crit Care Med; 2004 Jan; 32(1):53-60. PubMed ID: 14707559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization rate of carbapenems at intensive care units is not major determinant of gram-negative bacteria resistance to these antibiotics.
    Jankovic SM; Radonjic V
    J Infect; 2007 Nov; 55(5):480-1. PubMed ID: 17764746
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.
    Maseda E; Denis SE; Riquelme A; Gilsanz F
    Rev Esp Quimioter; 2013 Mar; 26(1):56-63. PubMed ID: 23546465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for managing today's infections.
    Carmeli Y
    Clin Microbiol Infect; 2008 Apr; 14 Suppl 3():22-31. PubMed ID: 18318876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.